New hope for Post-Transplant bladder bleeding: drug combo shows promise
NCT ID NCT01295645
First seen Jan 17, 2026 · Last updated Apr 29, 2026 · Updated 10 times
Summary
This study looks at whether adding the drug cidofovir to standard care can better control bladder bleeding caused by BK virus in people who have had a stem cell transplant. About 27 participants will be randomly assigned to receive either cidofovir plus standard care or standard care alone. The goal is to see if the combination leads to greater improvement in symptoms and reduction of the virus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSPLANTATION INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.